Volume : 09, Issue : 09, September – 2022

Title:

18.THE REVIEW ON PULSATILE DRUG DELIVERY SYSTEM
‬

Authors :

Prakash Shrawan Gaikwad, Dr. P. S. Kawtikwar

Abstract :

Pulsatile drug delivery systems (PDDS) are gaining importance as they deliver a drug at specific time as per the pathophysiological need of the disease, resulting in improved therapeutic efficacy as well as compliance. Diseases wherein PDDS are promising include asthma, peptic ulcer, cardiovascular diseases, arthritis, attention deficit syndrome in children, and hypercholesterolemia. These delivery systems can be classified into time controlled wherein the drug release is governed primarily by the delivery system; stimuli induced in which release is controlled by a stimuli, like the pH or enzymes present in the intestinal tract or enzymes present in the drug delivery system and externally regulated system where release is programmed by external stimuli like magnetism, ultrasound, electrical effect and irradiation. The current article focuses on the review of literature concerning the disease requiring PDDS, methodologies involved in the existing systems, recent update and product currently available in the market.
Key words: Lag time, pulsatile release, multiple unit-systems, chronotherapy, regulatory aspect

.

Cite This Article:

Please cite this article in Prakash Shrawan Gaikwad et al, The Review On Pulsatile Drug Delivery System., Indo Am. J. P. Sci, 2022; 09(9).

Number of Downloads : 10

References:

[1] Chen CM, inventor; Andrx Pharmaceuticals Inc, assignee. Multiparticulate pulsatile drug delivery system. United States patent US 5,508,040. 1996 Apr 16.
[2] Bodmeier R, Guo X, Sarabia RE, Skultety PF. The influence of buffer species and strength on diltiazem HC1 release from beads coated with the aqueous cationic polymer dispersions, Eudragit RS, RL 30D. Pharmaceutical research. 1996
;13(1):52-6.
[3] Schultz P, Kleinebudde P. A new multiparticulate delayed release system.: Part I: dissolution properties and release mechanism. Journal of controlled release. 1997 ;47(2):181-9.
[4] Beckert TE, Pogarell K, Hack I, Petereit HU. Pulsed drug release with film coatings of Eudragit & Mac226; RS 30D. InPrecede Int. Symp Control Release Bioact Mater 1999 ;26: 533-4
[5] Narisawa S, Nagata M, Danyoshi C, Yoshino H, Murata K, Hirakawa Y, Noda K. An organic acid-induced sigmoidal release system for oral controlled-release preparations. Pharmaceutical research. 1994 ;11(1):111-6.
[6] Guo X. Physicochemical and mechanical properties influencing the drug release from coated dosage forms (Doctoral dissertation, University of Texas at Austin).
[7] Narisawa S, Nagata M, Ito T, Yoshino H, Hirakawa Y, Noda K. Drug release behavior in gastrointestinal tract of beagle dogs from multiple unit type rate-controlled or time-controlled release preparations coated with insoluble polymer-based film. Journal of controlled release. 1995 ;33(2):253-60.
[8] Narisawa S, Nagata M, Hirakawa Y, Kobayashi M, Yoshino H. An organic acid‐ induced sigmoidal release system for oral controlled‐ release preparations. Journal of pharmaceutical sciences. 1996;85(2):184-8.
[9] Roy P, Shahiwala A. Multiparticulate formulation approach to pulsatile drug delivery: current perspectives. Journal of controlled release. 2009
;134(2):74-80.
[10] Lee DY, Chen CM, Anil K. Triggered Release of Bioactive Compounds, Recent Patents on Endocrine. Metabolic & Immune Drug Disc. 2007; 1:183-90.
[11] Singh A, Dubey H, Shukla I, Singh DP. Pulsatile drug delivery system: an approach of medication
according to circadian rhythm. J. App. Pharm. Sci. 2012; 2:166-76.
[12] Survase S, Kumar N. Pulsatile drug delivery: Current scenario. CRIPS. 2007 ;8(2):27-33.
[13] Gutowska A, Bark JS, Kwon IC, Bae YH, Cha Y, Kim SW. Squeezing hydrogels for controlled oral drug delivery. Journal of Controlled Release. 1997 ;48(2-3):141-8.
[14] Nobuhiko Y, Teruo O, Yasuhisa S. Inflammation responsive degradation of crosslinked hyaluronic acid gels. Journal of Controlled release. 1992
;22(2):105-16.
[15] Kikuchi A, Okano T. Pulsatile drug release control using hydrogels. Advanced drug delivery reviews. 2002 ;54(1):53-77.
[16] Miyata T, Asami N, Uragami T. A reversibly antigen-responsive hydrogel. Nature. 1999
;399(6738):766
according to circadian rhythm. J. App. Pharm. Sci. 2012; 2:166-76..
[17] Survase S, Kumar N. Pulsatile drug delivery: Current scenario. CRIPS. 2007 ;8(2):27-33.
[18] Gutowska A, Bark JS, Kwon IC, Bae YH, Cha Y, Kim SW. Squeezing hydrogels for controlled oral drug delivery. Journal of Controlled Release. 1997 ;48(2-3):141-8.
[19] Nobuhiko Y, Teruo O, Yasuhisa S. Inflammation responsive degradation of crosslinked hyaluronic acid gels. Journal of Controlled release. 1992
;22(2):105-16.
[20] Kikuchi A, Okano T. Pulsatile drug release control using hydrogels. Advanced drug delivery reviews. 2002 ;54(1):53-77.
[21] Miyata T, Asami N, Uragami T. A reversibly antigen-responsive hydrogel. Nature. 1999
;399(6738):766
[22] Hsieh DS, Langer R, Folkman J. Magnetic modulation of release of macromolecules from polymers. Proceedings of the National Academy of Sciences. 1981;78(3):1863-7.
[23] Edelman ER, Kost J, Bobeck H, Langer R. Regulation of drug release from polymer matrices by oscillating magnetic fields. Journal of biomedical materials research. 1985 ;19(1):67-83
[24] Kost J, Noecker R, Kunica E, Langer R. Magnetically controlled release systems: effect of polymer composition. Journal of biomedical materials research. 1985 19(8):935-40.
[25] Saslawski O, Weingarten C, Benoit JP, Couvreur
P. Magnetically responsive microspheres for the pulsed delivery of insulin. Life Sciences. 1988
;42(16):1521-8.
[26] Chen CM, inventor; Andrx Pharmaceuticals Inc, assignee. Multiparticulate pulsatile drug delivery system. United States patent US 5,508,040. 1996 Apr 16.
[27] Bodmeier R, Guo X, Sarabia RE, Skultety PF. The influence of buffer species and strength on diltiazem HC1 release from beads coated with the aqueous cationic polymer dispersions, Eudragit RS, RL 30D. Pharmaceutical research. 1996;13(1):52-6